{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T16:57:53Z","timestamp":1785430673111,"version":"3.56.0"},"reference-count":27,"publisher":"American Association for Cancer Research (AACR)","issue":"7","license":[{"start":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T00:00:00Z","timestamp":1784851200000},"content-version":"vor","delay-in-days":23,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100009812","name":"Princess Margaret Cancer Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009812","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,7,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title\/>\n                    <jats:p>Proton pump inhibitor (PPI) use has been associated with increased prostate cancer risk in case\u2013control and cohort studies of men with a negative prostate biopsy. We estimated the association of cumulative PPI use with prostate cancer diagnosis and outcomes in a biopsy-na\u00efve cohort of men using provincewide-linked administrative data from Ontario, Canada, including men \u226566 years with no prior prostate cancer diagnosis, biopsy, or treatment and no PPI\/histamine-2\u2013blocker prescriptions within the year preceding study inclusion (January 2003\u2013December 2018). The primary outcome was time to prostate cancer diagnosis. Associations were evaluated using univariable\/multivariable logistic regression models with complementary log\u2013log modeling. Median follow-up was 9.2 years (n = 559,425), and 30.2% had any PPI use during follow-up. Annual PPI use increased from 2.4% (2003) to 13.8% (2019). Cumulative PPI use was associated with lower prostate cancer diagnosis rates [hazard ratio (HR) for highest user quintile vs. nonusers: 0.75, 95% confidence interval (CI), 0.71\u20130.79]. Following adjustment for the frequency of general practitioner visits and prostate-specific antigen tests in the preceding 2 years, PPI use was no longer associated with prostate cancer diagnosis (HR, 0.99; 95% CI, 0.93\u20131.05). No association was observed between PPI use and rates of clinically significant or high-grade prostate cancer (HRs, 0.99 and 1.04, respectively). Cumulative PPI use was associated with up to 17% lower rates of a first androgen deprivation therapy prescription or bilateral orchiectomy. Cumulative PPI use was not associated with prostate cancer diagnosis rates, including clinically significant and high-grade prostate cancer. These findings do not support an independent association between PPI use and prostate cancer risk.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Significance:<\/jats:title>\n                    <jats:p>Among biopsy-na\u00efve older men, cumulative PPI use was not associated with prostate cancer diagnosis, including clinically significant and high-grade disease, after adjusting for healthcare resource utilization. These findings challenge prior observational signals suggesting increased risk and indicate that detection bias likely explains earlier associations.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1158\/2767-9764.crc-26-0098","type":"journal-article","created":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T19:08:43Z","timestamp":1782846523000},"page":"1769-1776","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Association of Cumulative Proton Pump Inhibitor Use with Prostate Cancer Risk and Outcomes: A Population-Based Cohort Study"],"prefix":"10.1158","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2133-569X","authenticated-orcid":false,"given":"Rashid K.","family":"Sayyid","sequence":"first","affiliation":[{"id":[{"id":"https:\/\/ror.org\/03m2x1q45","id-type":"ROR","asserted-by":"publisher"}],"name":"The University of Arizona 1 Department of Urology, , Banner University Medical Center, Tucson, Arizona."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3893-5859","authenticated-orcid":false,"given":"Raj","family":"Tiwari","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/05cqp3018","id-type":"ROR","asserted-by":"publisher"}],"name":"Sengkang General Hospital 2 Department of Urology, , Singapore, Singapore."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-5891-7594","authenticated-orcid":false,"given":"Bo","family":"Zhang","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/05p6rhy72","id-type":"ROR","asserted-by":"publisher"}],"name":"ICES 3 , Toronto, Canada."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0265-262X","authenticated-orcid":false,"given":"Andrew S.","family":"Wilton","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/05p6rhy72","id-type":"ROR","asserted-by":"publisher"}],"name":"ICES 3 , Toronto, Canada."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3760-5401","authenticated-orcid":false,"given":"Katherine","family":"Lajkosz","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/03zayce58","id-type":"ROR","asserted-by":"publisher"}],"name":"Princess Margaret Cancer Centre 4 Department of Biostatistics, , Toronto, Canada."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6308-0923","authenticated-orcid":false,"given":"Jessica Grace","family":"Cockburn","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/03zayce58","id-type":"ROR","asserted-by":"publisher"}],"name":"Princess Margaret Cancer Centre 5 Department of Surgical Oncology, , Toronto, Canada."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8076-4550","authenticated-orcid":false,"given":"Rui M.","family":"Bernardino","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/03zayce58","id-type":"ROR","asserted-by":"publisher"}],"name":"Princess Margaret Cancer Centre 5 Department of Surgical Oncology, , Toronto, Canada."},{"name":"6Division of Urology, Department of Surgical Oncology, University of Toronto, Toronto, Canada."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-9572-2353","authenticated-orcid":false,"given":"Zizo","family":"Al-Daqqaq","sequence":"additional","affiliation":[{"name":"7Division of Urology, Department of Surgery, The Ottawa Hospital, Ottawa, Canada."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8133-5459","authenticated-orcid":false,"given":"Linda Z.","family":"Penn","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/03zayce58","id-type":"ROR","asserted-by":"publisher"}],"name":"Princess Margaret Cancer Centre 8 , Toronto, Canada."},{"name":"9Department of Medical Biophysics, University of Toronto, Toronto, Canada."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5777-2138","authenticated-orcid":false,"given":"Hanan","family":"Goldberg","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/040kfrw16","id-type":"ROR","asserted-by":"publisher"}],"name":"SUNY Upstate Medical University 10 Department of Urology, , Syracuse, New York."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8641-7725","authenticated-orcid":false,"given":"Refik","family":"Saskin","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/05p6rhy72","id-type":"ROR","asserted-by":"publisher"}],"name":"ICES 3 , Toronto, Canada."},{"name":"11Institute of Health Policy, Management, and Evaluation, University of Toronto, Toronto, Canada."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7407-7463","authenticated-orcid":false,"given":"Neil E.","family":"Fleshner","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/03zayce58","id-type":"ROR","asserted-by":"publisher"}],"name":"Princess Margaret Cancer Centre 5 Department of Surgical Oncology, , Toronto, Canada."},{"name":"6Division of Urology, Department of Surgical Oncology, University of Toronto, Toronto, Canada."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1086","published-online":{"date-parts":[[2026,7,24]]},"reference":[{"key":"2026072400112776800_bib1","doi-asserted-by":"publisher","first-page":"17","DOI":"10.3322\/caac.21763","article-title":"Cancer statistics, 2023","volume":"73","author":"Siegel","year":"2023","journal-title":"CA Cancer J Clin"},{"key":"2026072400112776800_bib2","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1001\/jamainternmed.2019.0280","article-title":"Association of treatment with 5\u03b1-reductase inhibitors with time to diagnosis and mortality in prostate cancer","volume":"179","author":"Sarkar","year":"2019","journal-title":"JAMA Intern Med"},{"key":"2026072400112776800_bib3","doi-asserted-by":"publisher","first-page":"1792","DOI":"10.1056\/NEJMoa1201735","article-title":"Statin use and reduced cancer-related mortality","volume":"367","author":"Nielsen","year":"2012","journal-title":"N Engl J Med"},{"key":"2026072400112776800_bib4","doi-asserted-by":"publisher","first-page":"2514","DOI":"10.1002\/cam4.2025","article-title":"Metformin reduces prostate cancer risk among men with benign prostatic hyperplasia: a nationwide population-based cohort study","volume":"8","author":"Kuo","year":"2019","journal-title":"Cancer Med"},{"key":"2026072400112776800_bib5","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1016\/s0016-5085(00)70135-1","article-title":"Long-term omeprazole treatment in resistant gastroesophageal reflux disease: efficacy, safety, and influence on gastric mucosa","volume":"118","author":"Klinkenberg-Knol","year":"2000","journal-title":"Gastroenterology"},{"key":"2026072400112776800_bib6","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.japh.2020.09.015","article-title":"National trends in prescription proton pump inhibitor use and expenditure in the United States in 2002\u20132017","volume":"61","author":"Mishuk","year":"2021","journal-title":"J Am Pharm Assoc"},{"key":"2026072400112776800_bib7","doi-asserted-by":"publisher","first-page":"e56060","DOI":"10.1371\/journal.pone.0056060","article-title":"Proton pump inhibitor use in the U.S. ambulatory setting, 2002\u20132009","volume":"8","author":"Rotman","year":"2013","journal-title":"PLoS One"},{"key":"2026072400112776800_bib8","first-page":"354","article-title":"Deprescribing proton pump inhibitors: evidence-based clinical practice guideline","volume":"63","author":"Farrell","year":"2017","journal-title":"Can Fam Physician"},{"key":"2026072400112776800_bib9","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1038\/s41419-018-0642-6","article-title":"The proton pump inhibitor pantoprazole disrupts protein degradation systems and sensitizes cancer cells to death under various stresses","volume":"9","author":"Cao","year":"2018","journal-title":"Cell Death Dis"},{"key":"2026072400112776800_bib10","doi-asserted-by":"publisher","first-page":"832","DOI":"10.1038\/bjc.2015.17","article-title":"Effect of pantoprazole to enhance activity of docetaxel against human tumour xenografts by inhibiting autophagy","volume":"112","author":"Tan","year":"2015","journal-title":"Br J Cancer"},{"key":"2026072400112776800_bib11","doi-asserted-by":"publisher","first-page":"e017739","DOI":"10.1136\/bmjopen-2017-017739","article-title":"Maintenance therapy with proton pump inhibitors and risk of gastric cancer: a nationwide population-based cohort study in Sweden","volume":"7","author":"Brusselaers","year":"2017","journal-title":"BMJ Open"},{"key":"2026072400112776800_bib12","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1016\/j.canep.2018.02.004","article-title":"Maintenance proton pump inhibition therapy and risk of oesophageal cancer","volume":"53","author":"Brusselaers","year":"2018","journal-title":"Cancer Epidemiol"},{"key":"2026072400112776800_bib13","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1111\/apt.14796","article-title":"Proton pump inhibitor and histamine-2 receptor antagonist use and risk of liver cancer in two population-based studies","volume":"48","author":"Tran","year":"2018","journal-title":"Aliment Pharmacol Ther"},{"key":"2026072400112776800_bib14","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1016\/j.canlet.2019.02.028","article-title":"Proton pump inhibitors promote the growth of androgen-sensitive prostate cancer cells through ErbB2, ERK1\/2, PI3K\/Akt, GSK-3\u03b2 signaling and inhibition of cellular prostatic acid phosphatase","volume":"449","author":"Gesmundo","year":"2019","journal-title":"Cancer Lett"},{"key":"2026072400112776800_bib15","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1002\/pds.4702","article-title":"Proton pump inhibitor use and risk of breast cancer, prostate cancer, and malignant melanoma: an Icelandic population-based case-control study","volume":"28","author":"H\u00e1lfd\u00e1narson","year":"2019","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"2026072400112776800_bib16","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1038\/s41391-020-0248-9","article-title":"The deleterious association between proton pump inhibitors and prostate cancer-specific mortality \u2013 a population-based cohort study","volume":"23","author":"Goldberg","year":"2020","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"2026072400112776800_bib17","volume-title":"Evaluative Sciences","author":"Institute for Clinical","year":"2023"},{"key":"2026072400112776800_bib18","volume-title":"A reabstraction study to estimate the completeness and accuracy of data elements in the Ontario Cancer Registry","author":"Holowaty","year":"1996"},{"key":"2026072400112776800_bib19","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1016\/0895-4356(88)90052-2","article-title":"An application of capture-recapture methods to the estimation of completeness of cancer registration","volume":"41","author":"Robles","year":"1988","journal-title":"J Clin Epidemiol"},{"key":"2026072400112776800_bib20","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1111\/insr.12214","article-title":"A tutorial on multilevel survival analysis: methods, models and applications","volume":"85","author":"Austin","year":"2017","journal-title":"Int Stat Rev"},{"key":"2026072400112776800_bib21","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1038\/pcan.2011.29","article-title":"The impact of PSA testing frequency on prostate cancer incidence and treatment in older men","volume":"14","author":"Shao","year":"2011","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"2026072400112776800_bib22","doi-asserted-by":"publisher","first-page":"2733","DOI":"10.1002\/cncr.31337","article-title":"PSA screening, prostate biopsy, and treatment of prostate cancer in the years surrounding the USPSTF recommendation against prostate cancer screening","volume":"124","author":"Kearns","year":"2018","journal-title":"Cancer"},{"key":"2026072400112776800_bib23","doi-asserted-by":"publisher","first-page":"E1","DOI":"10.1002\/ijc.27811","article-title":"Inhibitors of vacuolar ATPase proton pumps inhibit human prostate cancer cell invasion and prostate-specific antigen expression and secretion","volume":"132","author":"Michel","year":"2013","journal-title":"Int J Cancer"},{"key":"2026072400112776800_bib24","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1111\/iju.14894","article-title":"Gut microbiome and prostate cancer","volume":"29","author":"Gujita","year":"2022","journal-title":"Int J Urol"},{"key":"2026072400112776800_bib25","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1016\/j.urology.2017.08.039","article-title":"The role of gut microbiome in the pathogenesis of prostate cancer: a prospective, pilot study","volume":"111","author":"Golombos","year":"2018","journal-title":"Urology"},{"key":"2026072400112776800_bib26","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1136\/gutjnl-2015-310376","article-title":"Proton pump inhibitors affect the gut microbiome","volume":"65","author":"Imhann","year":"2016","journal-title":"Gut"},{"key":"2026072400112776800_bib27","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1111\/apt.13568","article-title":"A comparison of the gut microbiome between long-term users and non-users of proton pump inhibitors","volume":"43","author":"Clooney","year":"2016","journal-title":"Aliment Pharmacol Ther"}],"container-title":["Cancer Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/doi\/10.1158\/2767-9764.CRC-26-0098\/3809599\/crc-26-0098.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/6\/7\/1769\/3814646\/crc-26-0098.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/6\/7\/1769\/3814646\/crc-26-0098.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T04:11:36Z","timestamp":1784866296000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article\/6\/7\/1769\/786991\/Association-of-Cumulative-Proton-Pump-Inhibitor"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,1]]},"references-count":27,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7,1]]}},"URL":"https:\/\/doi.org\/10.1158\/2767-9764.crc-26-0098","relation":{},"ISSN":["2767-9764"],"issn-type":[{"value":"2767-9764","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,1]]}}}